VIR Vir Biotechnology, Inc.

8-K Current Report

Filed: March 4, 2026

Health Care

Biological Products, (No Diagnostic Substances)

Vir Biotechnology, Inc. (VIR) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• CEO Marianne De Backer appointed to additional role of President effective March 4, 2026 — consolidating top executive positions
• No new compensation terms disclosed, no outside arrangements or conflicts of interest noted

+1 more insights

Other Vir Biotechnology, Inc. 8-K Filings

8-K Mar 2, 2026

8-K Feb 26, 2026

8-K Feb 23, 2026

Get deeper insights on Vir Biotechnology, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.